Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human parvovirus B19 vectors.

Kirsten A Weigel-Kelley1, Arun Srivastava

  • 1Department of Microbiology & Immunology, Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Pathologie-Biologie
|July 16, 2002
PubMed
Summary

Researchers engineered adeno-associated virus 2 vectors using parvovirus B19 capsids to target erythroid cells. While successful, a co-receptor is needed for efficient human hematopoietic cell infection by parvovirus B19.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Giant planum sphenoidale meningioma: rationale for Dolenc's step in the pterional approach.

Neurosurgical focus: Video·2026
Same author

mGem: AAV, from almost a virus to an awesome vector-or is it?

mBio·2026
Same author

Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India.

Human gene therapy·2025
Same author

Changing Spectrum of Invasive Fungal Infections of the Anterior Skull Base.

Journal of neurological surgery. Part B, Skull base·2024
Same author

Outcomes following surgical clipping of re-ruptured previously untreated intracranial aneurysms.

Neurosurgical review·2024
Same author

AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Area of Science:

  • Virology
  • Gene Therapy
  • Hematopoiesis

Background:

  • Human parvovirus B19 exhibits tropism for erythroid lineage cells.
  • Adeno-associated virus (AAV) vectors are utilized for gene delivery.
  • Targeting specific cell types like hematopoietic cells is crucial for gene therapy.

Purpose of the Study:

  • To develop a parvovirus B19 capsid-based vector for targeting erythroid lineage cells.
  • To investigate the tropism and transduction efficiency of engineered B19-AAV vectors.
  • To identify factors necessary for efficient B19 vector-mediated transduction of hematopoietic cells.

Main Methods:

  • Recombinant adeno-associated virus 2 genomes were packaged into parvovirus B19 capsids.
  • Transduction efficiency was assessed in primary human hematopoietic cells.

Related Experiment Videos

  • Cell surface receptor interactions were analyzed to understand tropism.

    • Main Results:

    • Efficient transduction of primary human erythroid lineage hematopoietic cells was achieved.
    • Low-level transgene expression was observed in non-erythroid cells.
    • P antigen is necessary but not sufficient for B19 vector transduction.

    Conclusions:

    • Parvovirus B19 capsid-based vectors can target erythroid cells.
    • A cell surface co-receptor, in addition to P antigen, is required for efficient B19 infection of hematopoietic cells.
    • Further research is needed to identify the putative co-receptor for optimizing B19 vector applications.